Compound Summary
leflunomide
Compound Information
leflunomide
Compound Name: | leflunomide |
Compound CID: | 3899 |
Synonyms: | leflunomide 75706-12-6 Arava lefunamide Leflunomida More... |
Iupac Name: | 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide |
InChI: | InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18) |
InChIKey: | VHOGYURTWQBHIL-UHFFFAOYSA-N |
Canonical Smiles: | CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F |
Isomeric Smiles: | CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F |
Molecular Weight: | 270.21 |
Molecular Formula: | C12H9F3N2O2 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
leflunomide
Molecular Weight: | 270.21 |
Molecular Formula: | C12H9F3N2O2 |
Hydrogen Bond Donor Count: | 1 |
Hydrogen Bond Acceptor Count: | 6 |
Rotatable Bond Count: | 2 |
Heavy Atom Count: | 19 |
Complexity: | 327 |
Synonyms
leflunomide
| leflunomide | leflunomide |
|---|---|
leflunomide |
75706-12-6 |
Arava |
lefunamide |
Leflunomida |
Leflunomidum |
5-methyl-N-4-(trifluoromethyl)phenyl-1,2-oxazole-4-carboxamide |
HWA 486 |
Leflunomidum INN-Latin |
HWA-486 |
SU101 |
Arava (TN) |
5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide |
5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide |
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide |
4-Isoxazolecarboxamide, 5-methyl-N-4-(trifluoromethyl)phenyl- |
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide |
UNII-G162GK9U4W |
SU-101 |
5-methyl-N-4-(trifluoromethyl)phenylisoxazole-4-carboxamide |
RS-34821 |
CHEMBL960 |
MLS000069648 |
CHEBI:6402 |
G162GK9U4W |
5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide) |
MFCD00867593 |
NCGC00015610-02 |
SMR000058209 |
5-methyl-N-4-(trifluoromethyl)phenyl-4-isoxazolecarboxamide |
4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl)- |
CAS-75706-12-6 |
DSSTox_CID_3201 |
DSSTox_RID_76923 |
DSSTox_GSID_23201 |
Leflunomida INN-Spanish |
SU 101 (pharmaceutical) |
Repso |
Lefunomide Inn-Spanish |
HSDB 7289 |
SR-01000000191 |
Arabloc |
HWA486 |
N-(4-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide |
L04AA13 |
Prestwick_87 |
Leflunomide USAN:USP:INN:BAN |
SU 101 |
SULOL |
Spectrum_000322 |
Opera_ID_1709 |
Prestwick0_000772 |
Prestwick1_000772 |
Prestwick2_000772 |
Prestwick3_000772 |
Spectrum5_000850 |
Lopac-L-5025 |
L 5025 |
SCHEMBL5057 |
BIDD:PXR0189 |
Lopac0_000649 |
BSPBio_000844 |
KBioSS_000802 |
Leflunomide, Immunosuppressant |
MLS001076267 |
DivK1c_000916 |
Leflunomide (JAN/USP/INN) |
SPECTRUM1503927 |
5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide |
SPBio_002783 |
BPBio1_000930 |
GTPL6825 |
ZINC4840 |
DTXSID9023201 |
HMS502N18 |
KBio1_000916 |
KBio2_000802 |
KBio2_003370 |
KBio2_005938 |
AOB5964 |
NINDS_000916 |
4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl |
HMS1570K06 |
HMS1922M06 |
HMS2090O12 |
HMS2097K06 |
HMS2235C07 |
HMS3262A19 |
HMS3268D12 |
HMS3371F21 |
HMS3414P03 |
HMS3654F07 |
HMS3673M17 |
HMS3678N21 |
HMS3714K06 |
HMS3865I13 |
Pharmakon1600-01503927 |
ALBB-019233 |
BCP22241 |
EBD46417 |
HY-B0083 |
Tox21_110182 |
Tox21_301873 |
Tox21_500649 |
BDBM50054601 |
DL-433 |
NSC677411 |
NSC759864 |
s1247 |
STL426823 |
AKOS000265193 |
Tox21_110182_1 |
AC-6796 |
BCP9000846 |
CCG-204736 |
CS-1781 |
DB01097 |
KS-1076 |
LP00649 |
MCULE-9490869974 |
NSC 677411 |
NSC 759864 |
NSC-677411 |
NSC-759864 |
SB17287 |
SDCCGSBI-0050629.P003 |
IDI1_000916 |
NCGC00015610-01 |
NCGC00015610-03 |
NCGC00015610-04 |
NCGC00015610-05 |
NCGC00015610-06 |
NCGC00015610-07 |
NCGC00015610-08 |
NCGC00015610-09 |
NCGC00015610-10 |
NCGC00015610-11 |
NCGC00015610-12 |
NCGC00015610-13 |
NCGC00015610-14 |
NCGC00015610-17 |
NCGC00015610-18 |
NCGC00015610-30 |
NCGC00022625-03 |
NCGC00022625-04 |
NCGC00022625-05 |
NCGC00022625-06 |
NCGC00022625-07 |
NCGC00022625-08 |
NCGC00255370-01 |
NCGC00261334-01 |
BM164612 |
H527 |
ST079287 |
Leflunomide 100 microg/mL in Acetonitrile |
AB0007396 |
A9622 |
AB00052389 |
EU-0100649 |
FT-0621959 |
L0250 |
SW196399-3 |
C07905 |
D00749 |
MLS-0003109.0001 |
AB00052389-17 |
AB00052389-18 |
AB00052389_19 |
AB00052389_21 |
706L126 |
Q248550 |
Q-201289 |
SR-01000000191-2 |
SR-01000000191-4 |
SR-01000000191-7 |
BRD-K78692225-001-03-9 |
BRD-K78692225-001-11-2 |
5-methyl-4-(4-trifluoromethyl-phenyl)aminocarbonylisoxazole |
5-methyl-4-(4-trifluoromethylphenyl)aminocarbonylisoxazole |
Leflunomide, European Pharmacopoeia (EP) Reference Standard |
N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide |
5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide; |
5-Methyl-N-4-(trifluoromethyl)-phenylisoxazole-4-carboxamide |
5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)-anilide |
N-(4-trifluoromethylphenyl)-5-methylisoxa-zole-4-carboxamide |
(5-methylisoxazol-4-yl)-N-4-(trifluoromethyl)phenylcarboxamide |
Isoxazole-4-carboxamide, 5-methyl-N-4-(trifluoromethyl)phenyl- |
Leflunomide, United States Pharmacopeia (USP) Reference Standard |
5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide;Leflunomide |
HWA486; RS-34821; SU101;HWA 486; RS 34821; SU 101 |
Leflunomide, Pharmaceutical Secondary Standard; Certified Reference Material |
Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard |
Experimental Data
leflunomide
| Species | Dose | Unit | Control(Avg days) | Treatment(Avg days) | Avg/Med Lifespan Change(%) | Control(Max days) | Treatment(Max days) | Max Lifespan Change(%) | Significant | Strain | Gender | PubMed | Avg/Med Lifespan Change tab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33.000000000000000 | umol/L | -7.000000000000000 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
leflunomide
Statistics Data
leflunomide
| Species | Avg/Med Lifespan Change(%) | Max Lifespan Change(%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | -7.000000000000000 | 1 | 1 |
Statistics Data Visualization
leflunomide
